Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug

Friday, 1 July 2022, 16:11:03
Celldex took aim at Roche and Novartis” blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.
— Investor”s Business Daily

Everything You Need to Know If You’re Worried About Recession

Friday, 1 July 2022, 09:34:31
This week, the Chairman of the Federal Reserve, Jerome Powell, spoke at an economic forum hosted by the European Central Bank and talked about inflation and efforts to combat it. In this video, let”s find what the Fed Chief said and what we can expect in the near future. Further in the video, we will talk about job cuts at JPMorgan (JPM), Novartis (NVS) and crypto firm Crypto.com. Finally, we will look at California’s inflation relief checks and the latest key economic data that could influence Fed’s next move in its battle against inflation.
— TipRanks

Novartis buys Mallinckrodt”s FDA voucher for $100M but remains mum on where to use its 7th PRV

Thursday, 30 June 2022, 20:17:26
Novartis on Thursday confirmed to Endpoints News that it purchased a priority review voucher from bankrupt pharma company Mallinckrodt, but the Swiss-American multinational company declined to elaborate on how it plans to use this 7th PRV. Under the terms of the deal, PRV market leader Novartis agreed to pay $65
— Endpoints News

Novartis opens new plant in Mumbai

Thursday, 30 June 2022, 19:16:09
Novartis on Friday said it has opened its new manufacturing plant for generic oral cancer medicines at Kalwe in Mumbai. Spread across 32,000 sqm, and housing state-of-the-art production technology, the plant is built to cater to export markets. It currently has a workforce of 70 people with plans to increase further to support the expansion of production capacity and capabilities.Built on a brownfield site, the plant has effluent treatment units installed to support sustainable manufacturing operations.Novartis said the plant, which marks a new chapter for its Sandoz business, will further strengthen the company’s operations in India and play a key role in driving global growth for its generics business.“Today marks an important milestone for us at Novartis, and particularly for our Sandoz division, a global leader in generic pharmaceuticals and biosimilars. The inauguration of the new production and launch site for Oncology oral solids at Kalwe in India is a step forward in our constant endeavour to pioneeraccess for patients by developing and commercializing novel, affordable approaches that address unmet medical needs,” said Sanjay Murdeshwar, country president, Novartis India.
— Economic Times India

Novartis weighs listing of $25B generic unit – Bloomberg

Thursday, 30 June 2022, 18:57:44
Swiss drugmaker, Novartis AG (NVS) (NVSEF) is said to be leaning towards a potential spinoff of its Sandoz business and a separate listing of the $25B generics drug unit is…
— Seeking Alpha